EGFR and ovarian cancer: Supportive studiesinclude PTEN small interfering RNA knockdown experiments in breast cancer cellsshowing increased AKT phosphorylation concordant with increased MK2206sensitivity5 and in vitro lung and ovarian cancer studiesdemonstrating synergistic inhibition of AKT and epidermal growth factor receptor(EGFR)/HER26.